On Jul. 31, 2020, Mesa Biotech announced it had been awarded a contract up to $15.4 million from the National Institutes of Health’s (NIH) Rapid Acceleration of Diagnostics (RADx) program for its Accula SARS-CoV-2 Test, which gives COVID-19 diagnostic results in 30 minutes at the point of care (POC).

The RADx program was established to extend the range and increase the availability of diagnostic tests for SARS-CoV-2, a critical component to safely getting Americans back together, including in the workplace, in schools and in life’s many venues.